Drugs & Aging

, Volume 22, Issue 9, pp 717–729

Effects of Inhaled Corticosteroids on Mortality and Hospitalisation in Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients

Appraising the Evidence
  • Jordana K. Schmier
  • Michael T. Halpern
  • Mechelle L. Jones
Leading Article
  • 61 Downloads

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are common conditions that have substantial effects on daily functioning and medical resource utilisation. In elderly populations, the use of inhaled corticosteroids (ICS) as a mainstay of treatment in asthma has long been accepted whereas the appropriateness and extent of use of ICS in COPD is not as clear. This paper reviews data associated with ICS treatment in the elderly, specifically characteristics of ICS users, rates of adherence, hospitalisation and mortality associated with ICS treatment.

Studies examining the use of ICS in asthma and COPD have generally found that ICS may be underused compared with guideline recommendations or that there are substantial differences between patients who receive ICS and those who do not. Among elderly asthma or COPD patients who receive ICS, there are lower rates of hospitalisation among those who adhere to their treatment plan. Among elderly patients with asthma, the combination of ICS plus long-acting β-adrenoceptor agonists has been shown to be superior in terms of mortality and hospitalisation compared with either treatment alone. There may be an interaction effect between oral corticosteroids and ICS among elderly COPD patients, although important differences may be present in the clinical characteristics of patients who receive one versus both forms of corticosteroids. A dose-response relationship between ICS and both all-cause and pulmonary-specific mortality has been shown among older COPD patients.

Several existing studies are subject to selection bias, as they have identified patients who survived for a specified period, for example, long enough to have received a specified number of prescriptions for ICS. This bias must be further explored. Future research should also clearly delineate asthma and COPD populations in order to identify different benefits from ICS. The use of a claims database that also includes clinical metrics would be useful to identify additional possible outcomes of ICS use. Further, symptom diaries or other patient-reported outcomes, such as health-related quality of life and health status, should be included in studies of ICS among the elderly to identify other benefits that should be considered in treatment selection.

References

  1. 1.
    Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2(1): 67–74PubMedCrossRefGoogle Scholar
  2. 2.
    Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003 May; 123(5): 1684–92PubMedCrossRefGoogle Scholar
  3. 3.
    Morbidity and mortality: 2004 chart book on cardiovascular, lung, and blood diseases [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. [Accessed 2004 Dec 13]
  4. 4.
    World Health Organization. Bronchial asthma: the scale of the problem. Fact sheet No. 206, 2000 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs206/en/ [Accessed 2005 Aug 3]
  5. 5.
    National Heart, Lung, and Blood Institute. Global Initiative for Asthma: global strategy for asthma management and prevention. NIH publication number 02-3659: updated 2002. Bethesda (MD): National Institutes of Health, 2002Google Scholar
  6. 6.
    Rich A. Corticosteroids and chronic obstructive pulmonary disease in the nursing home. J Am Med Dir Assoc 2004 Jan–Feb; 5(1): 31–37PubMedCrossRefGoogle Scholar
  7. 7.
    Pauwels RA, Barnes PJ. Pro-con debates on controversial clinical issues: inhaled corticosteroids are beneficial in COPD. Paper presented at Annual Meeting of the American Thoracic Society; 2002 May 20; Alatana (GA)Google Scholar
  8. 8.
    Balkrishnan R, Christensen DB. Inhaled corticosteroid nonadherence and immediate avoidable medical events in older adults with chronic pulmonary ailments. J Asthma 2000 Sep; 37(6): 511–7PubMedCrossRefGoogle Scholar
  9. 9.
    Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clin Ther 2000 Apr; 22(4): 452–69PubMedCrossRefGoogle Scholar
  10. 10.
    Blais L, Bourbeau J, Sheehy O, et al. Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. Can Respir J 2004 Jan–Feb; 11(1): 27–32PubMedGoogle Scholar
  11. 11.
    Bourbeau J, Ernst P, Cockcoft D, et al. Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur Respir J 2003 Aug; 22(2): 286–9PubMedCrossRefGoogle Scholar
  12. 12.
    Diette GB, Krishnan JA, Dominici F, et al. Asthma in older patients: factors associated with hospitalization. Arch Intern Med 2002 May 27; 162(10): 1123–32PubMedCrossRefGoogle Scholar
  13. 13.
    Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003 Dec 15; 168(12): 1488–94PubMedCrossRefGoogle Scholar
  14. 14.
    Jackevicius C, Joyce DP, Kesten S, et al. Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. Chest 1997 Feb; 111(2): 296–302PubMedCrossRefGoogle Scholar
  15. 15.
    Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001 Mar; 17(3): 337–42PubMedCrossRefGoogle Scholar
  16. 16.
    Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003 Feb; 21(2): 260–6PubMedCrossRefGoogle Scholar
  17. 17.
    Sin DD, Tu JV. Underuse of inhaled steroid therapy in elderly patients with asthma. Chest 2001 Mar; 119(3): 720–5PubMedCrossRefGoogle Scholar
  18. 18.
    Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001 Mar; 17(3): 380–5PubMedCrossRefGoogle Scholar
  19. 19.
    Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002 Oct; 20(4): 819–25PubMedCrossRefGoogle Scholar
  20. 20.
    Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003 Jul 1; 168(1): 49–53PubMedCrossRefGoogle Scholar
  21. 21.
    Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004 Mar; 23(3): 391–5PubMedCrossRefGoogle Scholar
  22. 22.
    Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma 1998; 35(6): 455–72PubMedCrossRefGoogle Scholar
  23. 23.
    Murray MD, Morrow DG, Weiner M, et al. A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother 2004 Mar; 2(1): 36–43PubMedCrossRefGoogle Scholar
  24. 24.
    van Walraven C, Davis D, Forster AJ, et al. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 2004 Jul; 57(7): 672–82PubMedCrossRefGoogle Scholar
  25. 25.
    Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004 Oct 1; 170(7): 760–5PubMedCrossRefGoogle Scholar
  26. 26.
    Donohue JF, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004; 3(3): 173–81PubMedCrossRefGoogle Scholar
  27. 27.
    Dal Negro RW, Pomari C, Tognella S, et al. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003; 16(4): 241–6CrossRefGoogle Scholar
  28. 28.
    Spencer S, Calverley PM, Sherwood Burge P, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 Jan; 163(1): 122–8PubMedGoogle Scholar
  29. 29.
    Halpern MT, Higashi MK, Bakst A, et al. The economic impact of acute exacerbations of chronic bronchitis (AECB) in the US and Canada: a literature review. J Manag Care Pharm 2003; 9(4): 353–9PubMedGoogle Scholar
  30. 30.
    Leidy NK, Rennard SI, Schmier JK, et al. The breathlessness, cough, and sputum scale (BCSS): the development of empirically-based guidelines for interpretation. Chest 2003; 124(6): 2182–91PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Jordana K. Schmier
    • 1
  • Michael T. Halpern
    • 1
  • Mechelle L. Jones
    • 1
  1. 1.Exponent Inc.AlexandriaUSA

Personalised recommendations